CytoMed Therapeutics Ltd

GDTC

Company Profile

  • Business description

    CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

  • Contact

    1 Commonwealth Lane
    No. 08-22 One Commonwealth
    Singapore149544
    SGP

    T: +65 62507738

    https://w2.cytomed.sg

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    34

Stocks News & Analysis

stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.
stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,179.9027.40-0.30%
CAC 408,258.9454.18-0.65%
DAX 4025,297.1355.26-0.22%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,235.293.65-0.04%
HKSE26,620.35224.61-0.84%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,240.77695.40-1.29%
NZX 50 Index13,629.2188.89-0.65%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,858.0025.70-0.29%
SSE Composite Index4,120.3718.460.45%

Market Movers